Pulmonx (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 7,879 Shares

Posted by Stanley Muller on Sep 3rd, 2026

Pulmonx Corporation (NASDAQ:LUNG – Get Free Report) insider Geoffrey Rose sold 7,879 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $17,806.54. Following the transaction, the insider owned 449,832 shares of the company’s stock, valued at $1,016,620.32. This represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Performance

Shares of NASDAQ LUNG traded down $0.02 during midday trading on Thursday, hitting $2.26. The company’s stock had a trading volume of 284,129 shares, compared to its average volume of 512,534. The stock has a fifty day moving average price of $1.79 and a 200 day moving average price of $1.56. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $97.07 million, a price-to-earnings ratio of -1.95 and a beta of 0.34.

Pulmonx (NASDAQ:LUNG – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. On average, research analysts forecast that Pulmonx Corporation will post -1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LUNG. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.67.

Check Out Our Latest Analysis on LUNG

Hedge Funds Weigh In On Pulmonx

Hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA bought a new stake in Pulmonx during the 2nd quarter worth approximately $5,996,000. ExodusPoint Capital Management LP purchased a new stake in Pulmonx in the 4th quarter worth approximately $4,312,000. Bank of America Corp DE boosted its holdings in Pulmonx by 60.3% in the 1st quarter. Bank of America Corp DE now owns 1,166,826 shares of the company’s stock valued at $1,505,000 after purchasing an additional 439,027 shares during the period. Almitas Capital LLC bought a new position in Pulmonx in the 2nd quarter valued at $1,383,000. Finally, BlackRock Inc. purchased a new position in shares of Pulmonx during the 2nd quarter valued at $1,147,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

(Get Free Report)

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.

Insider Buying and Selling by Quarter for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.